Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Albrioza sodium phenylbutyrate and ursodoxicoltaurine Amyotrophic lateral sclerosis (ALS) Reimburse with clinical criteria and/or conditions Complete
Brukinsa zanubrutinib Mantle cell lymphoma (MCL) Do not reimburse Complete
Xpovio selinexor Multiple myeloma Reimburse with clinical criteria and/or conditions Complete
Scemblix asciminib Philadelphia chromosome-positive chronic myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Spinraza nusinersen Spinal Muscular Atrophy Do not reimburse Complete
Vabysmo faricimab Macular degeneration, age-related Reimburse with clinical criteria and/or conditions Complete
Poteligeo mogamulizumab mycosis fungoides (MF), Sézary syndrome (SS) Reimburse with clinical criteria and/or conditions Complete
Cibinqo abrocitinib Atopic dermatitis, moderate to severe Reimburse with clinical criteria and/or conditions Complete
Tepmetko tepotinib Locally advanced or metastatic non-small cell lung cancer Do not reimburse Complete
Jemperli dostarlimab Endometrial cancer Do not reimburse Complete